PacBio Boosts Vega Output 50%, Slashes Sequencing Costs 40%
PACB sits 32% above its 52-week low of $1.09.
Summary
PacBio announced a major upgrade to its Vega benchtop sequencer with new SPRQ-Nx chemistry, boosting HiFi data output from 60 Gb to 90 Gb per run while cutting the U.S. list price per run from $1,100 to $995 — a roughly 40% reduction in cost per gigabase. The update also introduces faster two- and four-hour runs, expanded methylation calling, and compliance controls for regulated labs. This directly strengthens Vega's competitive position in targeted sequencing and could accelerate adoption in clinical and applied markets. The improvements follow a narrower Q1 loss and management's earlier guidance for a second-half ramp in instrument and consumable usage. Availability is planned by the end of August, setting up a potential catalyst for near-term orders.
At the time of this announcement, PACB was trading at $1.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $447.3M. The 52-week trading range was $1.09 to $2.73. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.